12 results on '"Barnett, Elizabeth"'
Search Results
2. Care of Immigrants
- Author
-
Barnett, Elizabeth D., primary
- Published
- 2015
- Full Text
- View/download PDF
3. Nelson’s Neonatal Antimicrobial Therapy
- Author
-
Joseph B. Cantey, MD, Jason Sauberan, John D. Nelson, Barnett Elizabeth, John S. Bradley, David W. Kimberlin, Paul E Palumbo, J. Howard Smart, William J Steinbach, Joseph B. Cantey, MD, Jason Sauberan, John D. Nelson, Barnett Elizabeth, John S. Bradley, David W. Kimberlin, Paul E Palumbo, J. Howard Smart, and William J Steinbach
- Subjects
- Newborn infants--Diseases--Treatment, Communicable diseases in newborn infants
- Abstract
Completely updated and revised, Nelson's Neonatal Antimicrobial Therapy, 2nd Edition, provides the most current, practical, and evidence-based recommendations for health care professionals treating neonates. Developed by leading experts in antimicrobial therapy, this resource aims to help clinicians select the right drug, dose, and duration for the treatment of bacterial, viral, fungal, and parasitic infections in neonates. Neonatal infectious disease therapeutics research continues to expand and respond to emerging novel pathogens and bacterial resistance. The recommendations in this book are based on the best available evidence to provide those taking care of neonates with the best possible treatment decisions, with updated guidance on dosing for low-birth-weight newborns, drug monographs for commonly prescribed drugs, and antimicrobial stewardship guidance for the nursery.
- Published
- 2024
4. 2024 Nelson’s Pediatric Antimicrobial Therapy
- Author
-
John S. Bradley, John D. Nelson, Barnett Elizabeth, Joseph B. Cantey, MD, David W. Kimberlin, Paul E Palumbo, Jason Sauberan, J. Howard Smart, William J Steinbach, John S. Bradley, John D. Nelson, Barnett Elizabeth, Joseph B. Cantey, MD, David W. Kimberlin, Paul E Palumbo, Jason Sauberan, J. Howard Smart, and William J Steinbach
- Subjects
- Antibacterial agents--Therapeutic use, Communicable diseases in children--Chemotherapy, Pediatrics
- Abstract
Completely updated and revised, the 30th edition of this best-selling reference provides instant access to the latest recommendations for treatment of infectious diseases in children. For each disease, the authors provide a commentary to help select the best of all antimicrobial choices. Drug descriptions cover all antimicrobial agents available today and include complete information about dosing regimens. Free updates are available at aap.org/Nelsons. New in the 30th Edition Updated multiple drug-resistant gram-negative pathogens treatment recommendations with newly approved antibiotics Newer antibiotics, beyond vancomycin, to treat MRSA infections Updates on children's influenza, COVID-19, and enterovirus treatments Updates on travelers'diarrhea Latest guidelines for treatment of invasive pediatric fungal infections New guidelines for treatment of pediatric bacterial arthritis Recommendations on hepatitis C virus and cytomegalovirus treatment options CHAPTERS INCLUDE Antimicrobial Therapy According to Clinical Syndromes Antimicrobial Therapy for Neonates Choosing Among Antibiotics Antifungal Agents Antiviral Agents Antiparasitic Agents Preferred Therapy for Specific Bacterial and Mycobacterial Pathogens; Fungal Pathogens; Viral Pathogens; and Parasitic Pathogens Approach to Antibiotic Therapy for Drug-Resistant Gram-Negative Bacilli and Methicillin-Resistant Staphylococcus aureus Systemic and Topical Antimicrobial Dosing and Dose Forms Sequential Parenteral-Oral Antibiotic Therapy (Oral Step-Down Therapy) for Serious Infections Antimicrobial Prophylaxis/Prevention of Symptomatic Infection Approach to Antibiotic Allergies Antibiotic Stewardship Antibiotic Therapy for Children With Obesity And more…
- Published
- 2024
5. 2023 Nelson’s Pediatric Antimicrobial Therapy
- Author
-
John S. Bradley, John D. Nelson, Barnett Elizabeth, Joseph B. Cantey, MD, David W. Kimberlin, Paul E Palumbo, Jason Sauberan, J. Howard Smart, William J Steinbach, John S. Bradley, John D. Nelson, Barnett Elizabeth, Joseph B. Cantey, MD, David W. Kimberlin, Paul E Palumbo, Jason Sauberan, J. Howard Smart, and William J Steinbach
- Subjects
- Antibacterial agents--Therapeutic use, Communicable diseases in children--Chemotherapy, Pediatrics
- Abstract
Completely updated and revised, the 29th edition of this best-selling reference provides instant access to the latest recommendations for treatment of infectious diseases in children. For each disease, the authors provide a commentary to help select the best of all antimicrobial choices.Drug descriptions cover all antimicrobial agents available today and include complete information about dosing regimens. CHAPTERS INCLUDE Antimicrobial Therapy According to Clinical SyndromesAntimicrobial Therapy for NeonatesChoosing AmongAntibioticsAntifungal AgentsAntiviral AgentsAntiparasitic AgentsOral Step-down Therapy for Serious InfectionsPrevention of Symptomatic InfectionApproach to Antibiotic AllergiesAntibiotic StewardshipAntibiotic Therapy for Children With Obesity
- Published
- 2023
6. 2022 Nelson’s Pediatric Antimicrobial Therapy
- Author
-
John S. Bradley, John D. Nelson, Barnett Elizabeth, Joseph B. Cantey, MD, David W. Kimberlin, Paul E Palumbo, Jason Sauberan, J. Howard Smart, William J Steinbach, John S. Bradley, John D. Nelson, Barnett Elizabeth, Joseph B. Cantey, MD, David W. Kimberlin, Paul E Palumbo, Jason Sauberan, J. Howard Smart, and William J Steinbach
- Subjects
- Communicable diseases in children--Chemotherapy--Handbooks, manuals, etc, Anti-infective agents--Handbooks, manuals, etc, Antibiotics--Handbooks, manuals, etc, Pediatrics
- Abstract
Completely updated and revised, the 28th edition of this best-selling reference provides instant access to the latest recommendations for treatment of infectious diseases in children. For each disease, the authors provide a commentary to help select the best of all antimicrobial choices. Drug descriptions cover all antimicrobial agents available today and include complete information about dosing regimens. TOPICS INCLUDE Antimicrobial Therapy by Clinical SyndromesAntimicrobial Therapy for NeonatesChoosing AmongAntibioticsAntifungal AgentsAntiviral AgentsAntiparasitic AgentsOral Step-down Therapy for Serious InfectionsPrevention of Symptomatic InfectionApproach to Antibiotic AllergiesAntibiotic StewardshipNew in the 28th EditionUpdated recommendations on acute hematogenous osteomyelitis, based on newly published guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America, including information on a decrease in the incidence of MRSA infections, allowing the recommendation of cefazolin, again, in empiric therapy for most pediatric bone infectionsUpdated recommendations on influenza treatment and prophylaxis, reflecting American Academy of Pediatrics guidance for 2021–2022Ceftazidime/avibactam now preferred over fluoroquinolones for treatment of Klebsiella pneumoniae carbapenemase–producing enteric bacilli, if susceptibleCefiderocol, a new iron-binding siderophore cephalosporin class, recently approved in adults for treatment of many drug-resistant pathogens, particularly Acinetobacter, Stenotrophomonas, and Pseudomonas; under study in childrenNew dosing for posaconazole suspension formulationNew approaches to mucormycosisAdded baloxavir for children 12+ years oldOnline updates of COVID-19 therapies once emergency use authorization in children at http://www.aap.org/nelsonsUpdated Nelson's app also available
- Published
- 2022
7. Care of Immigrants
- Author
-
Barnett, Elizabeth D., primary
- Published
- 2005
- Full Text
- View/download PDF
8. Comparison of ceftriaxone and trimethoprim-sulfamethoxazole for acute otitis media
- Author
-
Barnett, Elizabeth D., Teele, David W., Klein, Jerome O., Cabral, Howard J., and Kharasch, Sigmund J.
- Subjects
Acute otitis media -- Drug therapy ,Ceftriaxone -- Evaluation ,Co-trimoxazole -- Evaluation - Abstract
One injection of ceftriaxone appears to be equally effective in treating children with severe ear infections as a 10-day oral treatment with trimethoprim-sulfamethoxazole (TMP-SMZ). Four hundred eighty-four children with severe ear infections were given either a single injection of ceftriaxone or TMP-SMZ for 10 days. Three days after the beginning of treatment 95.1% of the children taking TMP-SMZ and 92.5% of those receiving a ceftriaxone injection were cured. Evaluations done two and four weeks after beginning treatment resulted in smaller but similar cure rates in the two groups., Objective. The purpose of this prospective, randomized, single-blind trial was to assess the clinical efficacy of a single intramuscular dose of ceftriaxone compared with 10 days of oral trimethoprim-sulfamethoxazole (TMP-SMZ) in treating acute otitis media (AOM). Methods. Children aged 3 months through 3 years diagnosed with AOM (signs of acute illness plus evidence of middle-ear effusion) were randomized to treatment with either a single intramuscular dose of ceftriaxone (maximum dose of 50 mg/kg) or 10 days of oral trimethoprim-sulfamethoxazole (8 mg of TMP and 40 mg of SMZ/kg/day in two divided doses). Children were evaluated at scheduled visits on days 3, 14, and 28, and the parents were telephoned on day 5. Children were assessed as cured, improved, or failed on day 3, and as cured or failed on days 14 and 28. Children ill at other times during the study period were, if possible, seen and assessed by the study team. Results. Of 596 children enrolled during the study period, 484 were evaluable. Characteristics of evaluable subjects did not differ significantly by drug. On day 3, 223/241 children in the ceftriaxone group (92.5%) and 231/243 (95.1%) in the TMP-SMZ group were cured or improved. On day 14, 158/197 (80.2%) in the ceftriaxone group and 174/212 (82.1%) in the TMP-SMZ group were cured. On day 28, 108/136 (79.4%) in the ceftriaxone group and 124/155 (80%) in the TMP-SMZ group were cured. Persistence of middle-ear fluid did not differ between groups at day 14 (55% in the ceftriaxone group vs 47% in the TMP-SMZ group; P = .16) or at day 28 (39% vs 43%; P = .48). Pain at the injection site persisting at day 3 occurred in 8.4% of children receiving ceftriaxone. New diarrhea was more common in the ceftriaxone group (23.6% vs 9.2%; P [is less than] .001). Conclusion. A single intramuscular dose of ceftriaxone is comparable in clinical efficacy to 10 days of oral TMP-SMZ for treatment of AOM. Pediatrics 1997;99:23-28; acute otitis media, ceftriaxone, short-course therapy., ABBREVIATIONS. TMP-SMZ, trimethoprim-sulfamethoxazole; AOM, acute otitis media; TM, tympanic membrane; MEF, middle-ear fluid. Otitis media is the most common reason, other than well-child visits, for children to be seen by [...]
- Published
- 1997
9. 2016 Nelson's Pediatric Antimicrobial Therapy, 22nd Edition
- Author
-
John S. Bradley, John D. Nelson, Joseph B. Cantey, MD, David W Kimberlin, Paul E Palumbo, Jason Sauberan, William J Steinbach, Barnett Elizabeth, John S. Bradley, John D. Nelson, Joseph B. Cantey, MD, David W Kimberlin, Paul E Palumbo, Jason Sauberan, William J Steinbach, and Barnett Elizabeth
- Subjects
- Children, Chemotherapy, Communicable diseases in children--Chemotherapy--Handbooks, manuals, etc, Antibiotics--Handbooks, manuals, etc, Anti-infective agents--Handbooks, manuals, etc, Infants
- Abstract
New 22nd Edition! This bestselling and widely used resource on pediatric antimicrobial therapy provides instant access to reliable, up-to-the-minute recommendations for treatment of all infectious diseases in children. For each disease, the authors provide a commentary to help health care providers select the best of all antimicrobial choices. Drug descriptions cover all antimicrobial agents available today and include complete information about dosing regimens. In response to growing concerns about overuse of antibiotics, the program includes guidelines on when not to prescribe antimicrobials.Practical, evidence-based recommendations from the experts in antimicrobial therapyDeveloped by distinguished editorial boardDesigned for those who take care of children and are faced with decisions every dayAt-a-glance tables of bacterial and fungal pathogen susceptibilities to commonly used antimicrobialsIncludes treatment of parasitic infections and tropical medicineUpdated assessments regarding the strength of the recommendation and the level of evidence for treatment recommendations for major infectionsAnti-infective drug listing, complete with formulations and dosagesAntibiotic therapy for obese childrenAntimicrobial prophylaxis/prevention of symptomatic infectionMaximal adult dosages and higher dosages of some antimicrobials commonly used in children
- Published
- 2016
10. Drinking Water to Prevent Postvaccination Presyncope in Adolescents: A Randomized Trial.
- Author
-
Kemper, Alex R., Barnett, Elizabeth D., Walter, Emmanuel B., Hornik, Christoph, Pierre-Joseph, Natalie, Broder, Karen R., Silverstein, Michael, and Harrington, Theresa
- Subjects
- *
AGE distribution , *ANXIETY , *DRINKING behavior , *IMMUNIZATION , *PAIN , *PEDIATRICS , *PROBABILITY theory , *QUESTIONNAIRES , *STATISTICAL sampling , *SYNCOPE , *WATER , *MULTIPLE regression analysis , *RANDOMIZED controlled trials , *DESCRIPTIVE statistics , *SYMPTOMS , *PREVENTION - Abstract
BACKGROUND AND OBJECTIVES: Postvaccination syncope can cause injury. Drinking water prephlebotomy increases peripheral vascular tone, decreasing risk of blood-donation presyncope and syncope. This study evaluated whether drinking water prevaccination reduces postvaccination presyncope, a potential syncope precursor. METHODS: We conducted a randomized trial of subjects aged 11 to 21 years receiving ≥1 intramuscular vaccine in primary care clinics. Intervention subjects were encouraged to drink 500 mL of water, with vaccination recommended 10 to 60 minutes later. Control subjects received usual care. Presyncope symptoms were assessed with a 12-item survey during the 20-minutes postvaccination. Symptoms were classified with a primary cutoff sensitive for presyncope, and a secondary, more restrictive cutoff requiring greater symptoms. Results were adjusted for clustering by recruitment center. RESULTS: There were 906 subjects randomly assigned to the control group and 901 subjects randomly assigned to the intervention group. None had syncope. Presyncope occurred in 36.2% of subjects by using the primary definition, and in 8.0% of subjects by using the restrictive definition. There were no significant differences in presyncope by intervention group for the primary (1-sided test, P = .24) or restrictive outcome (1-sided test, P = .17). Among intervention subjects vaccinated within 10 to 60 minutes after drinking all 500 mL of water (n = 519), no reduction in presyncope was observed for the primary or restrictive outcome (1-sided tests, P = .13, P = .17). In multivariable regression analysis, presyncope was associated with younger age, history of passing out or nearly passing out after a shot or blood draw, prevaccination anxiety, receiving >1 injected vaccine, and greater postvaccination pain. CONCLUSIONS: Drinking water before vaccination did not prevent postvaccination presyncope. Predictors of postvaccination presyncope suggest opportunities for presyncope and syncope prevention interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
11. Give first dose of HepB vaccine within 24 hours of birth: AAP.
- Author
-
Barnett, Elizabeth D.
- Published
- 2017
12. Illness in children after international travel: analysis from the GeoSentinel Surveillance Network.
- Author
-
Hagmann S, Neugebauer R, Schwartz E, Perret C, Castelli F, Barnett ED, and Stauffer WM
- Subjects
- Adolescent, Age Factors, Child, Child, Preschool, Communicable Disease Control, Confidence Intervals, Cross-Sectional Studies, Female, Geographic Information Systems, Hospitalization statistics & numerical data, Humans, Infant, Male, Odds Ratio, Population Surveillance, Sex Factors, United States, Communicable Diseases epidemiology, Communicable Diseases transmission, Developing Countries, Travel
- Abstract
Objective: By using a large, multicenter database, we investigated the characteristics and morbidities of 1591 children returning from 218 global destinations and presenting for care in 19 countries., Methods: Data reported to the GeoSentinel Surveillance Network between January 1997 and November 2007 were analyzed, to assess demographic features, travel characteristics, and clinical diagnoses of ill pediatric travelers. Data were compared between children and adults and among 3 pediatric age groups (0-5 years, 6-11 years, and 12-17 years)., Results: Children were predominantly tourist travelers returning from Asia, sub-Saharan Africa, or Latin America. Compared with adults, children disproportionately presented within 7 days after return, required hospitalization, lacked pretravel health advice, and had traveled for the purpose of visiting friends and relatives. Diarrhea (28%), dermatologic conditions (25%), systemic febrile illnesses (23%), and respiratory disorders (11%) accounted for the majority of diagnoses reported for children. No fatalities were reported. Diarrhea occurred disproportionately among children after exposure to the Middle East/North Africa, dermatologic conditions after exposure to Latin America, systemic febrile illnesses after exposure to sub-Saharan Africa or Asia, and respiratory disorders after exposure to Europe or North America. The proportionate morbidity rates of travel-associated diseases differed among the pediatric age groups and between children and adults., Conclusions: The health care utilization patterns before and after travel and the profiles of travel-associated health problems differed between children and adults. Health professionals providing pretravel advice need to consider destination- and age-specific susceptibility to travel-related morbidities and develop prevention strategies accordingly.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.